Jump Financial, LLC Editas Medicine, Inc. Transaction History

Jump Financial, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Oct 21, 2024	BUY	$6.25 - $11.11 $52,056 - $92,535	8,329 Added 42.0%	28,159 $285,000
Q4 2023 Feb 07, 2024	BUY	$6.25 - $11.11 $52,056 - $92,535	8,329 Added 42.0%	28,159 $285,000
Q3 2023 Oct 21, 2024	BUY	$6.92 - $9.31 $40,592 - $54,612	5,866 Added 42.01%	19,830 $154,000
Q3 2023 Nov 07, 2023	BUY	$6.92 - $9.31 $40,592 - $54,612	5,866 Added 42.01%	19,830 $154,000
Q2 2023 Oct 21, 2024	SELL	$6.36 - $11.47 $824,809 - $1.49 Million	-129,687 Reduced 90.28%	13,964 $114,000
Q2 2023 Aug 07, 2023	SELL	$6.36 - $11.47 $824,809 - $1.49 Million	-129,687 Reduced 90.28%	13,964 $114,000
Q1 2023 Oct 21, 2024	BUY	$7.03 - $11.53 $1.01 Million - $1.66 Million	143,651 New	143,651 $1.04 Million
Q1 2023 May 03, 2023	BUY	$7.03 - $11.53 $875,558 - $1.44 Million	124,546 Added 651.9%	143,651 $1.04 Million
Q4 2022 Feb 13, 2023	SELL	$8.32 - $13.21 $398,760 - $633,128	-47,928 Reduced 71.5%	19,105 $169,000
Q3 2022 Nov 07, 2022	SELL	$12.16 - $19.42 $22,508 - $35,946	-1,851 Reduced 2.69%	67,033 $821,000
Q2 2022 Aug 09, 2022	BUY	$9.99 - $21.35 $138,301 - $295,569	13,844 Added 25.15%	68,884 $815,000
Q1 2022 May 12, 2022	BUY	$14.08 - $27.63 $642,273 - $1.26 Million	45,616 Added 484.04%	55,040 $1.05 Million
Q4 2021 Feb 10, 2022	BUY	$26.55 - $40.57 $250,207 - $382,331	9,424 New	9,424 $250,000
Q2 2021 Aug 13, 2021	SELL	$31.29 - $56.64 $1.62 Million - $2.93 Million	-51,700 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $2.05 Million - $4.68 Million	51,700 New	51,700 $2.17 Million

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.